On May 31, 2026, Rallybio Corp entered into a merger agreement with Avenzo Therapeutics, where Avenzo will become a wholly-owned subsidiary of Rallybio, resulting in Avenzo shareholders owning approximately 56.6% of the combined company, while Rallybio shareholders will hold about 2.8%. This merger is intended to be tax-free, with a concurrent financing raising $215 million planned to support the transaction.